Technical Analysis for IMU - Imugene Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | -4.82% | |
| Wide Bands | Range Expansion | -4.82% | |
| Narrow Range Bar | Range Contraction | -7.06% | |
| Wide Bands | Range Expansion | -7.06% | |
| Oversold Stochastic | Weakness | -7.06% | |
| Lower Bollinger Band Walk | Weakness | -7.06% | |
| Wide Bands | Range Expansion | -7.06% | |
| Lower Bollinger Band Touch | Weakness | -7.06% | |
| Oversold Stochastic | Weakness | -7.06% |
| Alert | Time |
|---|---|
| Down 5% | about 8 hours ago |
| Down 3% | about 8 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
| Down 2% | about 9 hours ago |
| Down 1% | about 9 hours ago |
Get a Trading Assistant
Imugene Limited Description
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Gas Medicine Pharmaceutical Cancer Clinical Trial Biopharmaceutical Cancers Therapy Breast Cancer Oncology Tumor Tumors Biotechnology Companies Cancer Immunotherapy Health Technologies Antibodies Cancer Treatments Her2/Neu Immunotherapy Metastatic Breast Cancer Pancreatic Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.15 |
| 52 Week Low | 0.039 |
| Average Volume | 15,858,793 |
| 200-Day Moving Average | 0.088 |
| 50-Day Moving Average | 0.105 |
| 20-Day Moving Average | 0.094 |
| 10-Day Moving Average | 0.084 |
| Average True Range | 0.007 |
| RSI (14) | 37.50 |
| ADX | 31.36 |
| +DI | 10.415 |
| -DI | 36.026 |
| Chandelier Exit (Long, 3 ATRs) | 0.092 |
| Chandelier Exit (Short, 3 ATRs) | 0.090 |
| Upper Bollinger Bands | 0.116 |
| Lower Bollinger Band | 0.071 |
| Percent B (%b) | 0.17 |
| BandWidth | 48.188 |
| MACD Line | -0.008 |
| MACD Signal Line | -0.007 |
| MACD Histogram | -0.001 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.088 | ||||
| Resistance 3 (R3) | 0.088 | 0.086 | 0.087 | ||
| Resistance 2 (R2) | 0.086 | 0.083 | 0.086 | 0.086 | |
| Resistance 1 (R1) | 0.082 | 0.082 | 0.081 | 0.082 | 0.085 |
| Pivot Point | 0.080 | 0.080 | 0.079 | 0.080 | 0.080 |
| Support 1 (S1) | 0.076 | 0.077 | 0.075 | 0.076 | 0.073 |
| Support 2 (S2) | 0.074 | 0.076 | 0.074 | 0.072 | |
| Support 3 (S3) | 0.070 | 0.074 | 0.072 | ||
| Support 4 (S4) | 0.070 |
